Sustained reduction of MS disability: New player in comparing disease-modifying treatments

Affiliations

¹ From the Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD; and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (M.T.), Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. Bibi.Bielekova@nih.gov.
² From the Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD; and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (M.T.), Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

Editorial

Bibiana Bielekova et al. Neurology. 2016.

. 2016 Nov 8;87(19):1966-1967.

doi: 10.1212/WNL.0000000000003314. Epub 2016 Oct 12.

¹ From the Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD; and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (M.T.), Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain. Bibi.Bielekova@nih.gov.
² From the Neuroimmunological Diseases Unit (B.B.), National Institute of Neurological Disorders and Stroke, National Institute of Health, Bethesda, MD; and Centre d'Esclerosi Múltiple de Catalunya (Cemcat) (M.T.), Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Spain.

No abstract available

Publication types